|
Title
|
|
|
|
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Background: A prospective phase II study was conducted to evaluate the efficacy and toxicity of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer. Patients and methods: Patients had a maximum of three prior chemotherapy lines with no more than two prior platinum-containing regimens and a progression-free interval after the last dose of platinum <12 months. A total dose of 4 mg/m2/cycle (0.8 mg/m2/day from day 1 to day 5) was administered, repeated every 28 days. Results: From June 2005 to December 2005, 69 assessable patients were enrolled. The best overall response to study treatment by combined CA-125 and RECIST criteria was partial response in 17 patients (24.6%) and disease stabilization in 22 patients (31.9%). The median time to progression and overall survival were 3.8 and 16.2 months, respectively. A total of 312 cycles were administered. Neutropenia grade 4 and thrombocytopenia grade 4 occurred in 17.4% and 7.2% of patients, respectively. Diarrhea grade 4 was never observed. Asthenia and fatigue were reported by 36.2% and 18.8% of patients, but were all grade 2 or less. Conclusion: Gimatecan is a new active agent in previously treated ovarian cancer with myelosuppression as main toxicity. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Annals of oncology / European Society for Medical Oncology. - Amsterdam
| |
|
Publication
|
|
|
|
Amsterdam
:
2010
| |
|
ISSN
|
|
|
|
0923-7534
| |
|
Volume/pages
|
|
|
|
21
:4
(2010)
, p. 759-765
| |
|
ISI
|
|
|
|
000276045600013
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|